Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Alessandro Di Federico

University of Bologna

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (16)

Andréanne Gagné

Assistant Professor

Université Laval

CANADA

View details

Marco Tagliamento

Researcher/Assistant Professor

University of Genoa

ITALY

View details

María Isabel Loza García

Professor of Pharmacology with tenure

Universidade de Santiago de Compostela

SPAIN

View details

Seshiru Nakazawa

Gunma University

JAPAN

View details

Igor Odintsov

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

David J. Pinato

Imperial College London

UNITED KINGDOM

View details

Eleonora Balzani

University of Trento

ITALY

View details

Kyle Concannon

Assistant Professor

University of Colorado Cancer Center

UNITED STATES

View details

Natalie Vokes

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Antoine Italiano

Université Paris-Saclay

FRANCE

View details

Andrea De Giglio

University of Bologna

ITALY

View details

Alessandro Russo

Humanitas University

ITALY

View details

Bartlomiej Tomasik

Medical University of Gdansk

POLAND

View details

Jia Wu

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Pooja Gogia

Assistant Professor and Consultant

West Virginia University

UNITED STATES

View details

Giuseppe Perrone

Università Campus Bio-Medico di Roma

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alessandro Di Federico

Research Interests

Explore related searches

Articles (20)

Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors

Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer

Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data

<SUP>18</SUP>F-Fluorodeoxyglucose Uptake in <i>PDGFRA</i>-Mutant Gastrointestinal Stromal Tumors

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Assessing the benefit-to-risk ratio of first-line treatments for elderly patients (≥ 80 year-old) with advanced NSCLC

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations

Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study

Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

Collaborators (16)

Andréanne Gagné

Marco Tagliamento

María Isabel Loza García

Seshiru Nakazawa

Igor Odintsov

David J. Pinato

Eleonora Balzani

Kyle Concannon

Natalie Vokes

Antoine Italiano

Andrea De Giglio

Alessandro Russo

Bartlomiej Tomasik

Jia Wu

Pooja Gogia

Giuseppe Perrone

Make your next move.